BBIO News and Press, BridgeBio Pharma Inc. From 06/04/24

2024-06-04 14:46:03 ET Summary Revolution Medicines, Inc. stock has more than doubled since the market initially reacted negatively to a clinical update on its lead asset RMC-6236 in October 2023. The company's RAS(ON) inhibitors will be tested in two registrational trials for pan...

2024-06-04 11:42:04 ET More on BridgeBio Pharma BridgeBio Pharma: Upping An Existing Position (Rating Upgrade) BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident BridgeBio reports additional positive data for acoramidis in AT...

- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from baseline of +2.51cm/yr at Month 12, and +2.50 cm/yr at Month 18 (p=0.0015) - At Month 18...

PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children ...

2024-06-03 14:32:19 ET Summary Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200...

2024-06-03 14:14:05 ET Summary BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently. The company's primary drug candidate, Acoramidis, has a marketing application accepted by the FDA for ...

2024-05-29 20:54:18 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value decreased from $27.3B to $26.9B in Q1 2024. The number of holdings in the portfolio increased from 79 to 83. The largest five individual stock positions are Visa, Workday, Amazon.com, Philip Morri...

2024-05-29 17:11:50 ET More on BridgeBio Pharma BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident Cantor picks 14 undervalued biotech stocks worth a second look BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of ...

- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular-related hospitalization (CVH) in ATTR-CM participants through m...

2024-05-28 07:00:15 ET Eliana Merle from UBS issued a price target of $47.00 for BBIO on 2024-05-28 05:24:00. The adjusted price target was set to $47.00. At the time of the announcement, BBIO was trading at $27.94. The overall price target consensus is at $32.25 with hi...